Baudax Bio
A revenue-generating, specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Launch date
Employees
Market cap
CAD1.1m
Enterprise valuation
CAD1m (Public information from Mar 2024)
Share price
$0 BXRX
Pennsylvania United States (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | 1.1m | - | - | - | - |
| % growth | - | - | 119 % | - | - | - | - |
| EBITDA | (61.1m) | (53.2m) | (48.3m) | (17.9m) | - | - | - |
| % EBITDA margin | - | (10793 %) | (4469 %) | - | - | - | - |
| Profit | (32.6m) | (76.1m) | (19.8m) | (58.8m) | (6.3m) | (23.0m) | (23.5m) |
| % profit margin | - | (15436 %) | (1830 %) | - | - | - | - |
| EV / revenue | - | 12.0x | 11.3x | - | - | - | - |
| EV / EBITDA | -0.8x | -0.1x | -0.3x | -0.3x | - | - | - |
| R&D budget | 20.1m | 9.1m | 3.1m | 3.2m | - | - | - |
| R&D % of revenue | - | 1843 % | 289 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $25.0m | Post IPO Equity | |
| N/A | $11.9m | Post IPO Equity | |
| N/A | $4.2m | Post IPO Equity | |
* | N/A | $6.2m | Post IPO Equity |
* | N/A | $5.0m | Post IPO Equity |
* | N/A | $4.0m | Post IPO Equity |
* | N/A | $1.9m | Post IPO Equity |
| Total Funding | - | ||
